Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Rises By 227.3%

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 50,147 shares, a growth of 227.3% from the April 30th total of 15,320 shares. Based on an average daily trading volume, of 55,256 shares, the short-interest ratio is currently 0.9 days.

Ono Pharmaceutical Stock Down 1.1%

OTCMKTS OPHLY traded down $0.05 during trading on Friday, reaching $4.94. 28,498 shares of the company’s stock were exchanged, compared to its average volume of 26,316. The company has a 50 day moving average price of $5.08 and a two-hundred day moving average price of $4.92. Ono Pharmaceutical has a 1 year low of $3.35 and a 1 year high of $5.75.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.